setrusumab
UX143-CL307
Phase 3 mab active
Quick answer
setrusumab for Osteogenesis Imperfecta is a Phase 3 program (mab) at Ultragenyx Pharmaceutical with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Ultragenyx Pharmaceutical
- Indication
- Osteogenesis Imperfecta
- Phase
- Phase 3
- Modality
- mab
- Status
- active